Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma...
14 KB (1,047 words) - 03:31, 31 August 2024
(brand name Imbruvica, Pharmacyclics LLC) and one in October 2017, acalabrutinib (brand name Calquence, AstraZeneca Pharmaceuticals LP) were approved...
41 KB (4,549 words) - 08:59, 25 January 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
56 KB (5,566 words) - 13:30, 2 November 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
42 KB (3,486 words) - 00:32, 30 September 2024
treatments may be offered. As of 2021, BTK inhibitors such as ibrutinib and acalabrutinib are often recommended for first line treatment of CLL. The medications...
73 KB (7,597 words) - 22:02, 28 August 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
10 KB (778 words) - 01:56, 27 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
16 KB (1,287 words) - 20:48, 11 November 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
10 KB (703 words) - 17:18, 20 April 2024
rights to Acerta's irreversible oral Bruton's tyrosine kinase inhibitor, acalabrutinib (ACP-196), which is currently in Phase III development for B-cell blood...
92 KB (8,503 words) - 20:58, 17 November 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
31 KB (2,632 words) - 22:56, 26 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
8 KB (511 words) - 15:46, 7 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
79 KB (6,427 words) - 21:42, 14 November 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
8 KB (967 words) - 18:35, 12 August 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
53 KB (4,975 words) - 03:43, 30 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
31 KB (2,777 words) - 08:32, 19 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
44 KB (3,805 words) - 00:43, 23 July 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
6 KB (352 words) - 17:16, 16 May 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
42 KB (3,798 words) - 13:29, 20 November 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
91 KB (9,245 words) - 14:27, 17 November 2024
Cediranib L01EK03 Tivozanib L01EK04 Fruquintinib L01EL01 Ibrutinib L01EL02 Acalabrutinib L01EL03 Zanubrutinib L01EL04 Orelabrutinib L01EL05 Pirtobrutinib L01EM01...
12 KB (877 words) - 15:36, 25 January 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
214 KB (17,080 words) - 15:51, 27 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
16 KB (1,367 words) - 13:26, 14 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
10 KB (724 words) - 06:09, 16 July 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
14 KB (1,368 words) - 21:56, 12 September 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
41 KB (3,286 words) - 20:48, 11 November 2024
Ibrutinib (Imbruvica), a selective Bruton's tyrosine kinase inhibitor. Acalabrutinib (Calquence), approved in October 2017 for relapsed mantle cell lymphoma...
27 KB (2,837 words) - 12:09, 16 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
217 KB (21,648 words) - 17:51, 11 November 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
14 KB (718 words) - 14:56, 19 July 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
27 KB (2,911 words) - 19:56, 27 October 2024
v t e AstraZeneca Products Acalabrutinib Anastrozole Andexanet alfa Anifrolumab Asfotase alfa Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide...
9 KB (800 words) - 20:50, 24 October 2024